Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

56 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton.
Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. Sarbassov DD, et al. Among authors: guertin da. Curr Biol. 2004 Jul 27;14(14):1296-302. doi: 10.1016/j.cub.2004.06.054. Curr Biol. 2004. PMID: 15268862
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.
Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Sarbassov DD, et al. Among authors: guertin da. Science. 2005 Feb 18;307(5712):1098-101. doi: 10.1126/science.1106148. Science. 2005. PMID: 15718470
RNAi living-cell microarrays for loss-of-function screens in Drosophila melanogaster cells.
Wheeler DB, Bailey SN, Guertin DA, Carpenter AE, Higgins CO, Sabatini DM. Wheeler DB, et al. Among authors: guertin da. Nat Methods. 2004 Nov;1(2):127-32. doi: 10.1038/nmeth711. Epub 2004 Oct 21. Nat Methods. 2004. PMID: 15782175
An expanding role for mTOR in cancer.
Guertin DA, Sabatini DM. Guertin DA, et al. Trends Mol Med. 2005 Aug;11(8):353-61. doi: 10.1016/j.molmed.2005.06.007. Trends Mol Med. 2005. PMID: 16002336 Review.
Functional genomics identifies TOR-regulated genes that control growth and division.
Guertin DA, Guntur KV, Bell GW, Thoreen CC, Sabatini DM. Guertin DA, et al. Curr Biol. 2006 May 23;16(10):958-70. doi: 10.1016/j.cub.2006.03.084. Curr Biol. 2006. PMID: 16713952
Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1.
Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, Brown M, Fitzgerald KJ, Sabatini DM. Guertin DA, et al. Dev Cell. 2006 Dec;11(6):859-71. doi: 10.1016/j.devcel.2006.10.007. Dev Cell. 2006. PMID: 17141160
Defining the role of mTOR in cancer.
Guertin DA, Sabatini DM. Guertin DA, et al. Cancer Cell. 2007 Jul;12(1):9-22. doi: 10.1016/j.ccr.2007.05.008. Cancer Cell. 2007. PMID: 17613433 Review.
mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice.
Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, Sheen JH, Mullholland DJ, Magnuson MA, Wu H, Sabatini DM. Guertin DA, et al. Cancer Cell. 2009 Feb 3;15(2):148-59. doi: 10.1016/j.ccr.2008.12.017. Cancer Cell. 2009. PMID: 19185849 Free PMC article.
The pharmacology of mTOR inhibition.
Guertin DA, Sabatini DM. Guertin DA, et al. Sci Signal. 2009 Apr 21;2(67):pe24. doi: 10.1126/scisignal.267pe24. Sci Signal. 2009. PMID: 19383975
Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy.
Sparks CA, Guertin DA. Sparks CA, et al. Among authors: guertin da. Oncogene. 2010 Jul 1;29(26):3733-44. doi: 10.1038/onc.2010.139. Epub 2010 Apr 26. Oncogene. 2010. PMID: 20418915 Free PMC article. Review.
56 results
Jump to page
Feedback